热门资讯> 正文

Sensei Biotherapeutics GAAP每股收益-2.84美元

2026-08-04 19:49

Sensei Biotherapeutics, Inc.(SNSE) 0

Sensei Biotherapeutics press release (FTH): Q2 GAAP EPS of -$2.84.
Cash, cash equivalents and marketable securities increased to $186.4M as of June 30, 2026, from $21.2M at Dec. 31, 2025.
R&D expenses rose to $9.2M from $2.5M, driven by PIKTOR clinical trial, manufacturing and personnel costs, partly offset by lower SNS-101 trial costs.
G&A expenses increased to $9.2M from $2.7M, mainly due to higher personnel costs and professional fees related to financing and reporting.

More on Sensei Biotherapeutics

Most and least shorted healthcare stocks with market cap up to $2B at the end of May
Seeking Alpha’s Quant Rating on Sensei Biotherapeutics
Historical earnings data for Sensei Biotherapeutics
Financial information for Sensei Biotherapeutics

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。